Zhengye Corp - ZYBT Revenue Change YoY (Last 12 Months)

High confidence among Asian farmers in the quality of Zhengye Biotechnology (ZYBT) veterinary drugs serves as a powerful market signal. This TTM year-over-year revenue chart confirms this trend, with the indicator settling at -30.10. Growth is driven by new swine flu vaccines, while business stability is guaranteed by a strong team of biotech researchers motivated by government grants.
Summary analytical data breakdowns for Zhengye Bio (ZYBT)

For Zhengye Biotechnology (ZYBT), which provides biosecurity for livestock farming in Asia, rolling year revenue growth rates serve as an indicator of market share expansion and operational efficiency. By analyzing the rolling year-over-year sales growth trajectory, an investor assesses the actual speed of business scaling, noting that extreme peaks in this metric may signal a stock overvaluation driven by temporary hype.